jcar017
Cell therapyexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02631044)
Timeline
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- jcar017
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04245839 | Phase 2 | Apr 3, 2020 | Celgene |
| NCT03743246 | Phase 1/Phase 2 (Phase 2) | Oct 17, 2018 | Celgene |
| NCT03575351 | Phase 3 | Oct 16, 2018 | Celgene |
| NCT03484702 | Phase 2 | Jun 5, 2018 | Celgene |
| NCT03331198 | Phase 1/Phase 2 (Phase 2) | Dec 26, 2017 | Celgene, Juno Therapeutics, Inc. |
| NCT03310619 | Phase 1/Phase 2 (Phase 2) | Nov 28, 2017 | Celgene, Juno Therapeutics, Inc. |
| NCT02631044 | Phase 1 | Dec 1, 2015 | Juno Therapeutics, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 6 | 5 | 2 | 2017 |
| Juno Therapeutics, Inc. | For profit | 3 | 2 | 2 | 2015 |
2 organizations
Page 1 / 1